Breaking Down J&J's Fastest Growing Segment

Midsummer is considered prime beach season, but investors know that, more importantly, it's second-quarter earnings season.

With that in mind, this episode of The Motley Fool's Market Checkup is dedicated to the world's largest health-care conglomerate, Johnson & Johnson . Watch and find out how the second-quarter results of  Big Pharma stocks stack up, and what challenges and opportunities lie ahead for for each of its business segments.

In this video, health-care analysts David Williamson and Max Macaluso drill down on Johnson and Johnson's fastest-growing division: pharmaceuticals. Watch and find out why, after a few sleepy years, this division is showing robust growth on key product launches, including whether the company's strong performance can continue into the future.


Taking a break from the volatile biotech sector? Looking for ways to diversify into dividend-paying stocks? The Motley Fool's special report, "Secure Your Future With 9 Rock-Solid Dividend Stocks," is a great way to kick-start your search. Just click here to get your free copy today.

Follow David on Twitter: @MotleyDavid.

The article Breaking Down J&J's Fastest Growing Segment originally appeared on Fool.com.

David Williamson  owns shares of Johnson & Johnson. Follow David on Twitter: @MotleyDavid.Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.